jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Total hysterectomy with bilateral salphengo-oopherectomy Complex Biopsy

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Histology of uterus + adnexa.

₹1,110₹1,586

30% OFF

Total Hysterectomy with Bilateral Salpingo-Oophorectomy Complex Biopsy

  • Why is it done?
    • Test Description: This is a surgical procedure involving complete removal of the uterus, cervix, fallopian tubes, and both ovaries with comprehensive histopathological examination of the resected tissue and suspicious lesions. The complex biopsy component involves detailed microscopic analysis of multiple tissue samples to identify malignant or abnormal pathology.
    • Primary Indications: Suspected or confirmed gynecological malignancies (endometrial cancer, ovarian cancer, cervical cancer); persistent abnormal vaginal bleeding unresponsive to medical management; severe endometriosis; adenomyosis with debilitating symptoms; multiple fibroids causing significant symptoms; recurrent complex ovarian cysts; prevention of ovarian cancer in high-risk patients (BRCA mutations); persistent pelvic masses requiring definitive diagnosis
    • Typical Timing: Performed when definitive diagnosis and treatment are required; typically after imaging studies (ultrasound, MRI, CT) and clinical evaluation; often scheduled following abnormal Pap smears, elevated tumor markers, or imaging findings suggestive of malignancy; elective timing for prophylactic procedures in high-risk patients
  • Normal Range
    • Normal Findings: Benign endometrial tissue without hyperplasia or malignancy; normal myometrial muscle without adenomyosis; absence of neoplastic cells; normal cervical epithelium without dysplasia; healthy ovarian tissue without cysts or tumors; normal fallopian tube architecture; no evidence of metastatic disease
    • Negative Result Interpretation: Negative = Benign pathology with no evidence of malignancy; indicates successful treatment and removal of diseased tissue; favorable prognostic outcome; rules out invasive cancer in examined specimens
    • Positive Result Interpretation: Positive = Malignant cells identified; indicates presence of cancer requiring staging, additional treatment, and close follow-up; results guide adjuvant therapy decisions
    • Result Categories: Grade I-IV histological grading; Stage IA-IVB surgical staging; TNM classification for cancer staging; specific pathological diagnoses including adenocarcinoma, squamous cell carcinoma, sarcoma, or other malignancies
  • Interpretation
    • Benign Findings: Fibroids, endometriosis, adenomyosis, or polyps without atypia indicate disease successfully removed; prognosis is favorable; minimal recurrence risk; standard postoperative care sufficient
    • Malignant Findings Grade 1: Well-differentiated cancer; lowest grade of malignancy; favorable prognosis compared to higher grades; may require adjuvant chemotherapy or radiation depending on stage and lymph node involvement
    • Malignant Findings Grade 2: Moderately differentiated cancer; intermediate grade with moderate aggressiveness; intermediate prognosis; adjuvant therapy typically recommended; closer surveillance required
    • Malignant Findings Grade 3: Poorly differentiated cancer; highest grade with aggressive behavior; poor prognosis; multimodal therapy (surgery, chemotherapy, radiation) usually necessary; intensive follow-up and monitoring essential
    • Stage Determination: Stage I (localized to organ): generally favorable; Stage II (limited extension): intermediate outcome; Stage III (regional lymph node involvement): requires aggressive treatment; Stage IV (distant metastasis): poor prognosis requiring systemic therapy
    • Factors Affecting Interpretation: Surgical margins status; lymphovascular invasion; peritoneal cytology results; hormone receptor status; genetic mutations (HER2, BRCA); patient age and overall health; prior chemotherapy or radiation; presence of comorbidities
    • Special Findings: Lymph node metastases; peritoneal involvement; ascites cytology positive; clear surgical margins indicate better prognosis; positive margins suggest need for additional treatment
  • Associated Organs
    • Primary Organs Involved: Uterus (corpus and cervix); bilateral ovaries; fallopian tubes; associated pelvic ligaments and peritoneum; regional lymph nodes
    • Associated Conditions with Abnormal Results: Endometrial adenocarcinoma; ovarian epithelial cancers (serous, mucinous, clear cell, endometrioid); cervical cancer; uterine sarcomas; granulosa cell tumors; metastatic disease to pelvic organs; hereditary cancer syndromes (Lynch syndrome, BRCA-related); tamoxifen-induced endometrial cancer
    • Secondary Organs at Risk: Colon; small intestine; bladder; rectum (potential metastatic sites or surgical injury sites); liver; peritoneum; omentum
    • Potential Complications from Abnormal Results: Metastatic disease progression; peritoneal carcinomatosis; ascites accumulation; bowel obstruction; malnutrition; cachexia; renal failure from ureteral obstruction; sepsis from infection; hemorrhage; decreased survival if advanced staging identified
    • Endocrine Impact: Bilateral oophorectomy eliminates ovarian hormone production; immediate surgical menopause; requirement for hormone replacement therapy evaluation; increased cardiovascular and bone loss risk; potential for hormone-sensitive cancer recurrence if HRT utilized
    • Associated System Impact: Reproductive system elimination; loss of menstrual function; fertility permanently eliminated; sexual dysfunction potential; urinary incontinence or retention risk; bowel dysfunction; chronic pelvic pain syndrome
  • Follow-up Tests
    • Immediate Post-operative Testing: Complete blood count; comprehensive metabolic panel; liver function tests; coagulation studies; imaging (chest X-ray or CT chest/abdomen/pelvis if malignancy confirmed)
    • Cancer Staging Studies (if Malignancy Identified): Pelvic MRI or CT for local staging; abdominal and pelvic imaging; chest CT or X-ray for pulmonary metastases; PET-CT for metabolic activity assessment; tumor marker levels (CA-125, CEA, HER2)
    • Genetic and Molecular Testing: BRCA1/BRCA2 mutation analysis; Lynch syndrome testing; microsatellite instability testing; mismatch repair protein expression; hormone receptor analysis (ER/PR); HER2 status; molecular subtyping for targeted therapy selection
    • Specialized Pathology Review: Second opinion pathology review; immunohistochemistry studies; flow cytometry if indicated; electron microscopy for rare tumors; specialized staining for specific diagnoses
    • Oncology Consultation Tests: Tumor marker monitoring (CA-125 if elevated at baseline); serial imaging for surveillance; response assessment during chemotherapy; restaging studies at treatment completion
    • Monitoring Frequency: First 2 years: Every 3-4 months with imaging and labs; Years 3-5: Every 6 months; After 5 years: Annual surveillance; Benign pathology: Annual gynecological exam; standard cancer screening
    • Quality of Life and Symptom Assessment: Hormone replacement therapy evaluation; bone density assessment (DEXA scan); cardiovascular risk assessment; thyroid function tests (if considering HRT); psychological evaluation; sexual function assessment
    • Complementary Imaging: Ultrasound for surveillance; MRI for equivocal findings; colonoscopy if indicated for metastatic workup; cystoscopy if bladder involvement suspected
  • Fasting Required?
    • Fasting Status: YES - Fasting is required
    • Fasting Duration: Minimum 6-8 hours before surgery (typically nothing after midnight for morning procedures); water allowed up to 2 hours before surgery per anesthesia guidelines
    • NPO Status: NPO (Nothing by Mouth) after specified time; no solid foods, liquids, gum, or candy; clear liquids may be permitted up to 2-4 hours before procedure per institutional protocol
    • Medications to Continue: Cardiac medications (beta-blockers, ACE inhibitors) with small sip of water; seizure medications; respiratory medications; antidiabetic agents per surgical team guidelines; confirm with surgeon
    • Medications to Avoid/Hold: Anticoagulants (warfarin, aspirin, NSAIDs) 5-7 days prior per protocol; antiplatelet agents; herbal supplements (ginkgo, ginseng, garlic); hold on morning of surgery unless otherwise instructed; discuss with surgical team
    • Pre-operative Patient Preparation: Bowel preparation may be required (laxatives or enema); shower or bath night before with surgical scrub soap; mark operative site with marker; remove nail polish, makeup, and jewelry; empty bladder before pre-medication; wear hospital gown
    • Pre-operative Testing Required: Complete blood count; comprehensive metabolic panel; coagulation studies; urinalysis; EKG if >40 years or cardiac history; chest X-ray if >50 years or respiratory history; pregnancy test if applicable
    • Special Instructions: Informed consent discussion regarding outcomes and risks; anesthesia consultation if high-risk; venous thromboembolism prophylaxis discussion; pain management planning; arrange post-operative care and transportation; inform surgical team of all medications and allergies

How our test process works!

customers
customers